The pharmacological management of drug-induced rheumatic disorders

Bibliography

• VERGNE P, BERTIN P, BONNET C, SCOTTO C, TREVES R: Drug-Induced Rheumatic Disorders. Incidence, prevention and management. Drug Sal: (2000) 23(4):279–293.
   PubMedGoogle Scholar
• HOOPER DC,WOLFSON JS: Fluoroquinolone antimicrobial agents. N Engl. J. Med. (1991) 324:384–394.
   PubMed Web of Science ®Google Scholar
• HALKIN H: Adverse effects of the fluoroquinolones. Rev Infect. Dis. (1988) 10\(Supp1.1):S258–S261.
   Google Scholar
• ARCIERI G, GRIFFITH E, GURENWALDT G etal.: Ciprofloxacine: an update on clinical experience. Am. j Med. (1987) 82:381–386.
   Google Scholar
• LAFON M: Tendinopathies et fluoroquinolones. Concours Med. (1993) 115:819–825.
   Google Scholar
• LANOUX P, LEGIN C, REKSA A et al: Effets secondaires des fluoroquinolones. Etude retrospective sur l'annee (1992). Sem. Hon. Paris (1993) 69:1273–1276.
   Google Scholar
• GOUGH A, KASALI 0, SIGLER R et al: Quinolone arthropathy. Acute toxicity to immature articular cartilage. Toxicol Pathol (1992) 20(3):436–450.
   Google Scholar
• PRADHAN K, ARORA N, JENA A et al: Safety of ciproxoflacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr. (1995) 84:555–60.
   PubMed Web of Science ®Google Scholar
• STAHLMANN R, FORSTER C, VAN SICKLE D: Quinolones in children. Are concerns over arthropathy justified? Drug Sal (1993) 9(6):397–403.
   Google Scholar
• ZABRANIECKI L, NÉGRIER I, VERGNE P et al: Fluoroquinolone induced tendinopathy: report of 6 cases. Rheumatol (1996) 23:516–520.
   Google Scholar
• PELLETIER JP, DIBATTISTA J, RAYNAULD J et al: The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1, and oncogene protein synthesis in experimental osteoarthritis. Lab. Invest. (1995) 72(5):578–588.
   PubMedGoogle Scholar
• CALD WELL JR: Intraarticular corticosteroids. Drugs (1996) 52(4)507–514.
   Google Scholar
• GRAY RG,TENENBAUM J,GOTTLIEBNL: Local corticosteroid injection treatment in rheumatic disorders. Semi]. Arthritis Rheum. (1981) 10(4):231–254.
   PubMed Web of Science ®Google Scholar
• MACCARTY DJ, HOGAN JM: Inflammatory reaction after trasynovial injection of microcristalline adrenocorticosteroid. Arthritis Rheum. (1964) 7:359–367.
   PubMedGoogle Scholar
• HUNTER JA, BLYTH TH: A risk-benefitassessment of intra-articular corticosteroids in rheumatic disorders. Drug Sal: (1999) 21(5):353–365.
   PubMedGoogle Scholar
• OWEN DS: Aspiration, and injection of joints and soft tissues. In: Textbook of rheumatology (Edition 4). Kelley WN, Harris ED, Ruddy S etal. (Eds.), Saunders Company, Philadelphia, USA (1993)545–561.
   Google Scholar
• KROESEN S, SCHMID W, THEILER R: Induction of an acute attack of Calcium Pyrophosphate Dihydrate Arthritis by intra-articular injection of Hylan G-F 20 (Synvisc). Chit. Rheumatol (2000) 19:147–149.
   Google Scholar
• ALLEN E, KROHN K: Adverse reaction to Hylan GF-20. j Rheumatol (2000) 27(6):1572.
   PubMed Web of Science ®Google Scholar
• BERNARDEAU C, BUCKI B, LIOTE F: Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann. Rheum. Dis. (2001) 60(5):518–520.
   PubMed Web of Science ®Google Scholar
• KAPLAN G, HAETTICH B: Rheumatological symptoms due to retinoids. Bailleres Chit. Rheumatol (1991) 5(1):77–97.
   PubMedGoogle Scholar
• SAURAT JH: Systemic retinoids. What's new? Dermatol Gift]. (1998) 16:331–340.
   Google Scholar
• BRINDLEY CJ: An overview of recent clinical pharmacokinetic studies with acitretin (Ro-1670, etretin). Dermatologica (1989) 178:79–87.
   PubMedGoogle Scholar
• GEIGER JM, SAURAT JH: Acitretin and etretinate. How and when they should be used. Dermatol. Chit. (1993) 11:117–129.
   Google Scholar
• WIEGAND UW, CHOU RC: Pharmacokinetics of acitretin and etretinate. J. Am. Acad. Dermatol (1998) 39:S25–S33.
   Google Scholar
• GOLLNICK HP Oral retinoids: efficacy and toxicity in psoriasis. Br j Dermatol (1996) 135\(Suppl. 49):6–17.
   Google Scholar
• VAN DOOREN-GREEBE RJ, LEMMENS JA, DE BOO T et al: Prolonged treatment with oral retinoids in adults: no influence on the frequency of severity of spinal abnormalities. Br Dermatol (1996)134:71–76.
   PubMedGoogle Scholar
• STERN RS, FITZGERALD E, ELLIS CN et al: The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. j Am. Acad. Dermatol (1995) 33:44–52.
   PubMed Web of Science ®Google Scholar
• KATZ HI, WAALEN J, LEACH EE: Acitretin in psoriasis: an overview of adverse effects. j Am. Acad. Dermatol (1999) 41:S7–S12.
   PubMed Web of Science ®Google Scholar
• ORFANOS CE, ZOUBOULIS CC, ALMOND-ROESLER B, GEILEN CC: Current use and future potential role of retinoids in dermatology. Dugs (1997) 53:358–388.
   Google Scholar
• KELLEY WN, SCHUMACHER HR: Gout. In: Textbook of Rheumatology (4th ed. Kelley WN, Harris ED, Ruddy S et al, (Eds.), Saunders Company, Philadelphia, USA (1993):1291–1336.
   Google Scholar
• BANNWARTH B: The drug-induced rheumatism. Rev Rheum. (Eng. Ed.) (1996) 63(10):639–647.
   PubMedGoogle Scholar
• SCOTT JT: Drud-induced gout. Chit. Rheum. (1991) 5(1):39–60.
   PubMedGoogle Scholar
• BURACK DA, GRIFFITH BP, THOMPSON ME et al: Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am. j Med. (1992) 92:141–146.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN RS, BRYCE GF, SAPPINGTON LJ et al.: Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsivant drug treatment. j Chit. Endocnnol (1984) 58:1003–1009.
   PubMed Web of Science ®Google Scholar
• WOODSON GC: An interesting case of osteomalacia due to antiacid use associated with stainable bone aluminium in a patient with normal renal function. Bone (1998) 22:695–698.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG, COBURN JW, STALOPOLSKY E, SALUSKY IB: Renal osteodystrophy in adults and children. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. Favus MJ (Ed), American Society for Bone and Mineral Research, Kelseyville (1990):200–212.
   Google Scholar
• FLEISCH H: Biphosphonates: mechanismsof action. Endocrin Rev (1998) 19:80–100.
   PubMed Web of Science ®Google Scholar
• SCHNITZLER CM, SOMOMON L: Histomorphometric analysis of a calcaneal stess fracture: a possible complication of fluoride therapy for osteoporosis. Bone (1986) 7:193–198.
   PubMed Web of Science ®Google Scholar
• GRONOWICZ G, MCCARTY MB: Glucocorticoids inhibit the attachment of osteoblasts to bone extracellular matrix proteins and decreasel3-1 integrin levels. Endocrinology (1995) 136:598–608.
   PubMedGoogle Scholar
• FITZPATRICK LA: Glucocorticoid- induced osteoporosis. In: Osteoporosis. Marcus R (Ed.), Blackwell, Boston (1994):202–226.
   Google Scholar
• WEINSTEIN RS, JILKA RL, PARFITT AM, MANOLAGAS SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanism of their deleterious effects of bone. j Chit. Invest. (1998) 102:274–282.
   PubMed Web of Science ®Google Scholar
• MANKIN HJ: Nontraumatic necrosis of bone (osteonecrosis). N Engl. J Med. (1992) 326:1473–1429.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN RS, STAVROS C, MANOLAGAS SC. Apoptosis and osteoporosis. Am. j Med. (2000) 108:153–164.
   Google Scholar
• SHI XM, CHANG ZJ, BLAIR HC et al:Glucocorticoids induce adipogenesis of stromal cells by transcriptionally activating PPAR72. _J. Bone Miner. Res. (1998) 12:S454.
   Google Scholar
• PEEL NF, MOORE DJ, BARRINGTON NA, BAX DE, EASTELL R: Risk of vertebral fracture, relationship to bone mineral density in steroids treated rheumatoid arthritis. Ann. Rheum. Dis. (1995) 54:801–806.
   PubMed Web of Science ®Google Scholar
• SAMBROOK PN: Corticosteroid induced osteoporosis. j Rheumatol (1996) 23\(Suppl. 45):S19–S22.
   Google Scholar
• LO CASCIO V et al: Bone loss in response to long-term glucocorticoid therapy. Bone Miner. (1990) 8:39–51.
   PubMedGoogle Scholar
• JONES G, SAMBROOK PN: Drug-induced disorders of bone metabolism. Drug Sal: (1994) 10(6):480–489.
   PubMedGoogle Scholar
• COSMAN F, NIEVES J, HERBERT J et al.: High dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. j Bone Miner. Res. (1994) 9:1097–1105.
   PubMedGoogle Scholar
• REID IR, IBBERTSON HK: Calcium supplements in the prevention of steroid-induced osteoporosis. Am. j Chit. Num. (1986) 44:287–290.
   PubMed Web of Science ®Google Scholar
• ZAQQA D, JACKSON RD: Diagnosis and treatment of glucocorticoid-induced osteoporosis. Cleve. Clin. j Med. (1999) 66(4):221–230.
   PubMedGoogle Scholar
• HALL GM, DANIELS M, DOYLE DV, SPECTOR TD: Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. (1994) 37:1499–1505.
   PubMedGoogle Scholar
• REID IR, WATTIE DJ, EVANS MC et al.: Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. (1996) 156:1173–1177.
   PubMed Web of Science ®Google Scholar
• WOLFHAGEN FH, VAN BUUREN HR, DEN OUDEN JW et al: Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. j. Hepatol. (1997) 26:325–330.
   Google Scholar
• ADACHI JD, BENSEN WG, BROWN J et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl. I Med. (1997) 337:382–387.
   PubMed Web of Science ®Google Scholar
• SAAG KG, EMKEY RD, GRUBER B et al.: Alendronate for the management of gluco)corticoid-induced osteoporosis: results of the multicenter US study. Arthritis Rheum. (1997) 40:S136.
   Google Scholar
• COHEN S, LEVY RM, KELLER M et al.:Risedronate therapy prevents corticoid-induced bone loss. A twelve month, multicenter, randomized, double-bind, placebo-controlled, parallel-group study. Arthritis Rheum. (1999) 42:2309–2318.
   PubMed Web of Science ®Google Scholar
• LUENGO M, PONS E MARTINEZ DE, OBASA MJ, PICADO C: Prevention of further bone mass loss by nasal calcitonine in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax (1994) 49:1099–1102.
   PubMed Web of Science ®Google Scholar
• ADACHI JD, BENSEN WG, BELL MJ et al.: Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br. j Rheumatol (1997) 36:255–259.
   PubMedGoogle Scholar
• LEMS WF, JOBS WG et al: Effect of sodium fluoride on the prevention of corticoid-induced osteoporosis. Osteoporos. Int. (1997) 7:575–582.
   PubMedGoogle Scholar
• RIZZOLI R, CHE VALLEY T, SLOSMAN DO, BONJOUR JP: Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos. Int. (1995) 5:39–46.
   PubMedGoogle Scholar
• NEER RM, ARNAUD CD, ZANCHETTA JR et al: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl. J Med. (2001) 344(19):1434–1441.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology taskforce on osteoporosis guidelines. Recommandations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. (1996) 39(11):1791–801.
   PubMedGoogle Scholar
• ADINOFF AD, HOLLISTER JR: Steroid-induced fractures and bone loss in patients with asthma. N Engl. I Med. (1983) 309:265–268.
   PubMed Web of Science ®Google Scholar
• GLUCK OS, MURPHY WA, HAHN TJ, HAHN BH: Bone loss in adults receiving alternate day glucocorticoid therapy: a comparison with daily therapy. Arthritis Rheum. (1981) 24:892–898.
   PubMed Web of Science ®Google Scholar
• LE GOFF P, SARAUX A: Induced lupus. Rev. Rhum. (1999) 66(1):40–45.
   Google Scholar
• YUNG RL, JOHNSON KJ, RICHARDSON BC:Biology of disease: New concepts in the pathogenesis of drug-induced lupus. Lab. Investig. (1995) 73(6):746.
   PubMedGoogle Scholar
• DE BANDT M, DESCAMPS V, PALAZZO E, MEYER 0: Lupus eryhtemateux dissémine induit par l'etanercept au cours d'une polyarthrite rhumatokle. Rev. Rhum. (Ed Fr) (2000) 67(9):834.
   Google Scholar
• MARKHAM A, LAMB HM: Inffiximab: a review of its use in the management of rheumatoid arthritis. Drugs (2000) 59(6):1341–1359.
   PubMed Web of Science ®Google Scholar
• TINGLE AJ, ALLEN M, PETTY RE et al.: Rubella-associated arthritis. Comparative study of joint manifestations associated with natural rubella infection and RA 27:3 rubella immunisation. Ann. Rheum. Dis. (1986) 45:606–612.
   Google Scholar
• MAILLEFERT JF, SIBILIA J, TOUSSIROT E et al.: Arthropathies epees vaccin contre l'hépatite B. Rev Rhum. (1998) 65\(Suppl. 5):5246–5247.
   Google Scholar
• POPE JE, STEVENS A, HOWSON W et al.: The development of rheumatoid arthritis after recombinant hepatitis B vaccination; j Rheumatol (1998) 25:1687–1693.
   Google Scholar
• BUCHS N, CHEVREL G, MIOSSEC P: Bacillus Calmette-Guerin induced aseptic arthritis: an experimental model of reactive arthritis. j Rheumatol (1998) 25 (9) :1662–1664.
   PubMedGoogle Scholar
• PICHERT G, JOST LM, ZOBELI L et al: Thyroiditis after treatment with interleukin-2 and interferon alpha 2a. Br j Cancer (1990) 62:00–104.
   Google Scholar
• MIOSSEC P: Cytokine-induced autoimmune disorders. Dug Sal: (1997) 17(2):93–104.
   PubMedGoogle Scholar
• O'CONNELL PG, GERBER LH, DIGIOVANNA JJ et al: Arthritis in 1630Expert Op/n. Pharmacother. (2001) 2(10) patients with psoriasis treated with gamma-interferon. j. Rheumatol. (1992) 19:80–82.
   Google Scholar
• VIDARSSON B, GEIRSSON AJ, ONUNDARSON PT: Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. Am. I Med. (1995) 98:589–591.
   Google Scholar
• ZABRANIECKI L, DOUB A, MULARCZYCK M. et al.: Frozen shoulder: a new delayed complication of protease inhibitors therapy. Rev Rhum. (1998) 65:72–74.
   Google Scholar
• PEREZ RS, KWAKKEL G, ZUURMOND WW, de LANGE JJ: Treatment of reflex sympathetic dystrophy (CPRS Type I): a research synthetis on 21 randomized clinical trials. j. Pain Symptom Manage. (2001) 21(6):511–526. Affiliation Claire Scotto Di Fazanot, P Bertin, Vergne E Bonnet C & R Treves t Author for correspondence Department of Rheumatology and Therapeutic, University Hospital Dupuytren, Limoges, France
   Google Scholar